Fosamprenavir
- Generic Name
- Fosamprenavir
- Brand Names
- Lexiva, Telzir
- Drug Type
- Small Molecule
- Chemical Formula
- C25H36N3O9PS
- CAS Number
- 226700-79-4
- Unique Ingredient Identifier
- WOU1621EEG
- Background
Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.
- Indication
Indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a...
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR
- Conditions
- First Posted Date
- 2002-08-19
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00043888
- Locations
- ๐ฌ๐ง
GSK Clinical Trials Call Center, Manchester, United Kingdom
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
- First Posted Date
- 2002-07-10
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 69
- Registration Number
- NCT00040664
- Locations
- ๐ช๐ธ
GSK Investigational Site, Valencia, Spain
Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People
- Conditions
- First Posted Date
- 2001-12-28
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 56
- Registration Number
- NCT00028366
- Locations
- ๐บ๐ธ
USC CRS, Los Angeles, California, United States
๐บ๐ธThe Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
๐บ๐ธCase CRS, Cleveland, Ohio, United States
Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV
- Conditions
- First Posted Date
- 2001-12-05
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 53
- Registration Number
- NCT00027339
- Locations
- ๐บ๐ธ
USC CRS, Los Angeles, California, United States
๐บ๐ธUC Davis Medical Center, Sacramento, California, United States
๐บ๐ธBeth Israel Med. Ctr., ACTU, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.